Bamco Inc. NY Decreases Stock Holdings in Tempus AI, Inc. (NASDAQ:TEM)

Bamco Inc. NY lowered its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 71.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 225,800 shares of the company’s stock after selling 558,597 shares during the period. Bamco Inc. NY owned about 0.15% of Tempus AI worth $12,780,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TEM. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI during the third quarter valued at approximately $30,000. Sandia Investment Management LP purchased a new position in Tempus AI during the 2nd quarter valued at $136,000. Vestor Capital LLC bought a new position in Tempus AI in the 3rd quarter worth $153,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of Tempus AI in the 3rd quarter worth about $258,000. Finally, Clarus Group Inc. bought a new stake in shares of Tempus AI during the 3rd quarter valued at about $283,000.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $62.94 on Tuesday. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock has a 50 day moving average price of $53.31.

Analysts Set New Price Targets

A number of research firms recently issued reports on TEM. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Needham & Company LLC restated a “buy” rating and set a $47.00 price target on shares of Tempus AI in a research report on Wednesday, August 7th. Bank of America lowered Tempus AI from a “buy” rating to a “neutral” rating and raised their price objective for the company from $45.00 to $60.00 in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. upped their target price on shares of Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Loop Capital increased their price target on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and an average price target of $54.22.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.